Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Tuberculosis

  Free Subscription


Articles published in Respir Med

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    June 2020
  1. KANG H, Jo KW, Jeon D, Yim JJ, et al
    Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea.
    Respir Med. 2020;167:105956.
    PubMed     Abstract available


    February 2020
  2. SONG WM, Li YF, Liu JY, Tao NN, et al
    Drug resistance of previously treated tuberculosis patients with diabetes mellitus in Shandong, China.
    Respir Med. 2020;163:105897.
    PubMed     Abstract available


  3. PEREIRA GR, Barbosa MS, Dias NJD, Dos Santos FF, et al
    Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
    Respir Med. 2020;162:105876.
    PubMed     Abstract available


    January 2020
  4. IM Y, Lee J, Kim SJ, Koh WJ, et al
    Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors.
    Respir Med. 2020;161:105853.
    PubMed     Abstract available


  5. PIUBELLO A, Souleymane MB, Hassane-Harouna S, Yacouba A, et al
    Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.
    Respir Med. 2020;161:105844.
    PubMed     Abstract available


    October 2019
  6. HUANG CT, Lee MR, Ruan SY, Tsai YJ, et al
    Prognostic value of the mitogen response in the interferon-gamma release assay in patients with culture-confirmed tuberculosis.
    Respir Med. 2019;158:49-54.
    PubMed     Abstract available


    September 2019
  7. NOH CS, Kim HI, Choi H, Kim Y, et al
    Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
    Respir Med. 2019;157:52-58.
    PubMed     Abstract available


    June 2019
  8. FURUUCHI K, Morimoto K, Yoshiyama T, Tanaka Y, et al
    Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan.
    Respir Med. 2019;152:74-80.
    PubMed     Abstract available


    April 2019
  9. LEE E, Shim JY, Kim HY, Suh DI, et al
    Clinical characteristics and etiologies of bronchiectasis in Korean children: A multicenter retrospective study.
    Respir Med. 2019;150:8-14.
    PubMed     Abstract available


    February 2019
  10. BAN GY, Jeong YJ, Lee SH, Shin SS, et al
    Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications.
    Respir Med. 2019;147:44-50.
    PubMed     Abstract available


    January 2019
  11. YOO IY, Huh HJ, Kang OK, Jhun BW, et al
    Advantages of the AdvanSure MDR-TB GenoBlot assay containing disputed rpoB mutation-specific probes in a routine clinical laboratory setting.
    Respir Med. 2019;146:71-75.
    PubMed     Abstract available


    September 2018
  12. AZNAR ML, Zubrinic M, Siemienowicz M, Hashimoto K, et al
    Adjuvant lung resection in the management of nontuberculous mycobacterial lung infection: A retrospective matched cohort study.
    Respir Med. 2018;142:1-6.
    PubMed     Abstract available


    June 2018
  13. SUN F, Li L, Liao X, Yan X, et al
    Adjunctive use of prednisolone in the treatment of free-flowing tuberculous pleural effusion: A retrospective cohort study.
    Respir Med. 2018;139:86-90.
    PubMed     Abstract available


    February 2018
  14. SIKJAER MG, Lokke A, Hilberg O
    The influence of psychiatric disorders on the course of lung cancer, chronic obstructive pulmonary disease and tuberculosis.
    Respir Med. 2018;135:35-41.
    PubMed     Abstract available


    January 2018
  15. SILVA DR, Sotgiu G, D'Ambrosio L, Pereira GR, et al
    Diagnostic performances of the Xpert MTB/RIF in Brazil.
    Respir Med. 2018;134:12-15.
    PubMed     Abstract available


    December 2017
  16. KIM S, Lee H, Park HY, Jeon K, et al
    Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
    Respir Med. 2017;133:6-11.
    PubMed     Abstract available


    November 2017
  17. BOTHAMLEY GH, Lange C
    Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study.
    Respir Med. 2017;132:68-75.
    PubMed     Abstract available


    October 2017
  18. PARK S, Jo KW, Lee SD, Kim WS, et al
    Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Respir Med. 2017;131:43-48.
    PubMed     Abstract available


    April 2017
  19. JO KW, Yeo Y, Sung H, Kim MN, et al
    Corrigendum to "Analysis of discrepant results between the Genotype(R) MTBDRplus assay and an antimicrobial-susceptibility test for isoniazid-resistant tuberculosis'"[Respiratory Med. 122 (January 2017) 12-17].
    Respir Med. 2017;125:24.
    PubMed    


    January 2017
  20. JO KW, Yeo Y, Sung H, Kim MN, et al
    Analysis of discrepant results between the Genotype(R) MTBDRplus assay and an antimicrobial drug susceptibility test for isoniazid-resistant tuberculosis.
    Respir Med. 2017;122:12-17.
    PubMed     Abstract available


    October 2016
  21. CERVANTES J
    Tuberculosis. Digging deep in the soul of humanity.
    Respir Med. 2016;119:20-22.
    PubMed     Abstract available


    July 2016
  22. DIMAKOU K, Triantafillidou C, Toumbis M, Tsikritsaki K, et al
    Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients.
    Respir Med. 2016;116:1-7.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: